Merck KGaA Lifts Guidance a Third Time, Even as Net Profit Halves

A third upgrade this year says the underlying business is outrunning the one-off gains that flattered last year's profit.

Sources

Sources & evidence

What “Source checked” means

Merck KGaA, the German science and technology group, said third-quarter net sales rose 5.8% to €5.63 billion, ahead of the €5.46 billion consensus.

Net sales reached €5.63 billion on a reported basis, with organic growth of 5.1%. The print is about 3.1% above the Vara mean of €5.46 billion, a TickerGrove calculation.

EBITDA pre (adjusted EBITDA excluding one-time items) rose 0.8% on a reported basis to €1.68 billion. Organic growth in the measure was 0.4%, the company said.

Against the Vara consensus mean of €1.61 billion, the exact result is about 4.7% above expectations, a TickerGrove calculation. The mean is published on the company's own investor page.

EPS pre, the adjusted per-share measure, was €2.32, unchanged from the year-earlier quarter. That sits above the Vara consensus mean of €2.22, also published by the company.

Merck KGaA is based in Darmstadt, Germany, and works across life science, healthcare and electronics. It is a separate company from Merck & Co. of Rahway, New Jersey.

A third raise, on performance, currency and a pending deal

Merck now expects full-year net sales of €21.5 billion to €21.9 billion. That is up from its previous range of €21.0 billion to €21.8 billion.

Full-year EBITDA pre is now guided at €6.2 billion to €6.4 billion. The previous range was €5.9 billion to €6.3 billion, and the raise is the third this year.

EPS pre is now guided at €8.30 to €8.70 for the year, on the same adjusted basis. That replaces a range of €7.90 to €8.60 in the previous outlook.

Organic sales growth for the year is now expected at 3% to 4%, up from 1% to 3%. Earlier raises this year came alongside the first- and second-quarter results.

The company tied the raise to better underlying performance and more favorable currency effects. The guidance also incorporates Bio-Techne as a Life Science portfolio effect, assuming a December 2026 closing.

The company itself flags that the actual closing date may differ. Until it closes, the December contribution is an assumption inside the guidance, not recorded revenue.

Merck agreed in June to buy Bio-Techne for $11.3 billion, its biggest deal in more than a decade. The acquisition would add to its Life Science unit, which makes drug research and manufacturing tools.

“Our upgraded full-year guidance reflects our confidence that Merck will continue to deliver solid performance in 2026,” Chief Executive Kai Beckmann said.

Net profit halved against a flattered year-earlier quarter

Reported net profit fell 50% to €450 million in the quarter, a decline of 49.9% on exact figures. The year-earlier quarter had benefited from one-off gains, which flatters the comparison.

On the earnings call, the comparison base was spelled out in detail. The year-earlier quarter included a €60 million gain from a priority review voucher sale and a €59 million legislative tailwind in South America.

Two one-time effects in the year-earlier quarter each added a mid-double-digit million euro amount. That is the company's own framing of why the reported comparison is demanding.

Life Science led, Electronics surged, Healthcare inched up

Life Science was the largest business, with net sales of €2.41 billion and organic growth of 6.1%. Demand for pharmaceutical-process services drove the unit during the quarter.

Electronics net sales were €948 million, with organic growth of 13.3%. Within Electronics, Semiconductor Solutions sales were €752 million, up 18.7% organically on chip-materials demand.

Merck supplies specialty materials and chemical solutions used to produce advanced microchips. Those materials underpin artificial intelligence applications and data centers, a demand pool the company highlighted.

Healthcare net sales were €2.27 billion, with organic growth of 0.9%. Rare-disease drugs supported the unit, even as Mavenclad erosion accelerated in the United States.

Management warned of a steep Mavenclad decline in 2027, as generic competition reaches the multiple-sclerosis treatment. The healthcare business is also losing patent protection on key drugs, Dow Jones reported.

Segment guidance moved with the group ranges. Life Science organic growth is now guided at 6% to 7%, Electronics at 10% to 11%, and Healthcare to an organic decline of 2% to 3%.

What to watch: Bio-Techne's close, Mavenclad and Thursday's close

What to watch first is whether Bio-Techne closes in December, as the guidance assumes. A later close would remove a support the new ranges already count on.

In Thursday morning trading on Xetra, shares rose about 2.2% to €154.88, as of about 09:27 UTC. That is an intraday reading, not a close: Thursday's Xetra close is the first settled verdict.

Whether Vara consensus estimates move up toward the new guidance is the next test. Before the report, the Vara full-year mean sat near the low end of both new ranges.

What remains unknown

Whether Bio-Techne closes in December, as the guidance assumes, remains unknown. The deal is still pending, and a slip would change the arithmetic behind the raise.

How steep the 2027 Mavenclad decline will be also remains unknown. Management flagged the direction on the call without quantifying the drop.

Thursday's settled Xetra close and the next Vara consensus are likewise not yet known. Both will show how much of the third raise investors and analysts accept.

Sources & evidence

Source checked6 sources · 26 figures

Figure receipts

Every figure in this article, with the source it came from.

  • 5627 Merck KGaA net sales, third quarter 2026, reported

    EUR · million euros · As of Nov. 12, 2026

  • 5.8 growth in Merck KGaA net sales, third quarter 2026, reported, year over year

    % · As of Nov. 12, 2026

  • 5.1 organic growth in Merck KGaA net sales, third quarter 2026

    % · As of Nov. 12, 2026

  • 1682 Merck KGaA EBITDA pre, adjusted excluding one-time items, third quarter 2026

    EUR · million euros · As of Nov. 12, 2026

  • 0.8 growth in Merck KGaA EBITDA pre, third quarter 2026, reported, year over year

    % · As of Nov. 12, 2026

  • 0.4 organic growth in Merck KGaA EBITDA pre, third quarter 2026

    % · As of Nov. 12, 2026

  • 2.32 Merck KGaA EPS pre, adjusted, third quarter 2026, unchanged year over year

    EUR · euros per share · As of Nov. 12, 2026

  • 450 Merck KGaA net profit after tax, third quarter 2026, reported

    EUR · million euros · As of Nov. 12, 2026

  • 49.9 decline in Merck KGaA net profit, third quarter 2026, year over year, exact

    % · As of Nov. 12, 2026

  • 8.30 Merck KGaA full-year 2026 EPS pre guidance, low end, adjusted

    EUR · euros per share · As of Nov. 12, 2026

  • 8.70 Merck KGaA full-year 2026 EPS pre guidance, high end, adjusted

    EUR · euros per share · As of Nov. 12, 2026

  • 5459.1 Vara consensus mean for Merck KGaA net sales, third quarter 2026

    EUR · million euros · As of Nov. 12, 2026

  • 3.1 Merck KGaA net sales versus the Vara consensus mean, TickerGrove calculation

    % · As of Nov. 12, 2026

  • 1606 Vara consensus mean for Merck KGaA EBITDA pre, third quarter 2026

    EUR · million euros · As of Nov. 12, 2026

  • 4.7 Merck KGaA EBITDA pre versus the Vara consensus mean, TickerGrove calculation on exact figures

    % · As of Nov. 12, 2026

  • 2.22 Vara consensus mean for Merck KGaA EPS pre, third quarter 2026

    EUR · euros per share · As of Nov. 12, 2026

  • 2411 Merck KGaA Life Science net sales, third quarter 2026

    EUR · million euros · As of Nov. 12, 2026

  • 6.1 Merck KGaA Life Science organic sales growth, third quarter 2026

    % · As of Nov. 12, 2026

  • 948 Merck KGaA Electronics net sales, third quarter 2026

    EUR · million euros · As of Nov. 12, 2026

  • 18.7 Merck KGaA Semiconductor Solutions organic sales growth, third quarter 2026

    % · As of Nov. 12, 2026

  • 154.88 Merck KGaA share price in Thursday morning Xetra trading, intraday at about 09:27 UTC, not a close

    EUR · euros · As of Nov. 12, 2026

  • 21.5 Merck KGaA full-year 2026 net sales guidance, low end

    EUR · billion euros · As of Nov. 12, 2026

  • 21.9 Merck KGaA full-year 2026 net sales guidance, high end

    EUR · billion euros · As of Nov. 12, 2026

  • 6.2 Merck KGaA full-year 2026 EBITDA pre guidance, low end, adjusted

    EUR · billion euros · As of Nov. 12, 2026

  • 6.4 Merck KGaA full-year 2026 EBITDA pre guidance, high end, adjusted

    EUR · billion euros · As of Nov. 12, 2026

  • $11.3B agreed value of the Bio-Techne acquisition, announced June 2026

    As of Nov. 12, 2026

All dates 2026.

TickerGrove house illustration for healthcare coverage: a double helix

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Companies · All stories